Why Bausch + Lomb Stock Is Back on Investors’ Radar
Bausch + Lomb (BLCO) has drawn fresh attention after recent trading left the shares about 14% lower over the past month and roughly 8% lower over the past 3 months, which has sharpened focus on its current valuation.
See our latest analysis for Bausch + Lomb.
Over the past year, Bausch + Lomb has combined a 5.93% total shareholder return with recent share price pressure, including a 13.83% 1 month share price decline. This suggests momentum has cooled as investors reassess growth prospects and risks around the current US$15.89 level.
If this shift in sentiment has you looking beyond a single eye care name, it may be a good moment to widen your watchlist and uncover 36 healthcare AI stocks
With Bausch + Lomb trading at US$15.89, an intrinsic value gap of about 56% and a market value near US$5.7b, the key question is simple: are you looking at a genuine opportunity or a stock where markets already expect stronger growth?
Most Popular Narrative: 7.9% Undervalued
The most followed narrative currently pegs Bausch + Lomb’s fair value at $17.25, a shade above the recent $15.89 close and framed using an 8.9% discount rate.
An aging population driving more cataract and premium refractive procedures, combined with the rapid recovery and expansion of high margin premium IOL platforms such as enVista Envy and LuxSmart, is expected to accelerate Surgical segment growth and support overall gross margin expansion.
Want to see what sits behind that premium eye surgery thesis? The narrative leans heavily on revenue mix, margin repair and a future profit profile that needs to justify a rich earnings multiple on later year estimates.
Result: Fair Value of $17.25 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, there is still a chance that faster than expected dry eye prescription growth or stronger premium IOL recovery could quickly shift sentiment and put pressure on this narrative.
Find out about the key risks to this Bausch + Lomb narrative.
Next Steps
If the mixed signals around Bausch + Lomb have you on the fence, this is a good moment to act quickly and test the numbers yourself, starting with 3 key rewards
Ready for more investment ideas?
If Bausch + Lomb is only one piece of your watchlist, now is the time to scan for other opportunities before the next move leaves you catching up.
- Target value focused opportunities by checking stocks highlighted in the 61 high quality undervalued stocks that combine quality fundamentals with attractive pricing.
- Strengthen the foundation of your portfolio by reviewing companies in the solid balance sheet and fundamentals stocks screener (39 results) that prioritize financial resilience.
- Spot potential future leaders early by searching through the screener containing 25 high quality undiscovered gems before the wider market catches on.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com